Zanubrutinib and venetoclax combination shows an 87% 36-month PFS rate in CLL/SLL patients, regardless of del (17p)/TP53 or IGHV status. The SEQUOIA trial demonstrates durable minimal residual disease ...

Privately-held Imvax, a biotech developing personalized, whole tumor-derived immunotherapies, has announced top line results ...

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically ...

For those with ALK+ NSCLC who received first-line, next-generation ALK TKI monotherapy, continuing ALK TKI with chemotherapy is linked to better outcomes.

Daiichi Sankyo has announced the dosing of first patient in the DESTINY-Ovarian01 Phase III trial’s randomisation phase, ...

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing ...

In October 2025, Samsung Bioepis announced that the company will assume full commercial responsibility for BYOOVIZ in Europe upon full transition of Biogen’s commercialization rights back to Samsung ...

Among nearly 3,000 patients, those treated with PA-PPIs such as omeprazole (Prilosec) or pantoprazole (Protonix) had worse progression-free survival (PFS) and overall survival (OS), reported Emilie Le ...

An ECOG-ACRIN imaging study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring ...

Estate planning clients turn to AI to save money but risk costly mistakes. Professional advisors offer expertise AI lacks ...

VEN+O is a cost-effective treatment for untreated, fit CLL patients, offering superior progression-free survival and cost savings compared to most alternatives. The study used a cost-utility analysis, ...

Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus ...